Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2015

Open Access 01-12-2015 | Study protocol

Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokers

Authors: Doug Fraser, Ron Borland, Coral Gartner

Published in: BMC Public Health | Issue 1/2015

Login to get access

Abstract

Background

Smoking is Australia’s leading preventable cause of premature mortality and a major contributor to the national disease burden. If quit rates do not dramatically improve, then smoking will continue to be a major public health issue for decades to come. Harm-reduction approaches using novel nicotine products like e-cigarettes as long term replacements for smoking have the potential to improve quit rates. However, little research has assessed such approaches.

Methods/Design

Design: Three-arm parallel-group pragmatic randomised controlled trial.
Participants : People living in Australia who are at least 18 years old, smoke five or more cigarettes per day and are willing to try a sample of nicotine products.
Intervention: Participants are randomised to receive standard quit advice and medicinal nicotine (Condition A); quit or substitute advice and medicinal nicotine (Condition B); or quit or substitute advice and medicinal nicotine and e-cigarettes (Condition C). Participants choose which (if any) nicotine products to receive to try in a free sample pack followed by a two to three week free supply of their favourite product(s) and the option to purchase more at a discounted price. Follow-up surveys will assess nicotine product use and smoking.
Primary outcome: Continuous abstinence for at least 6 months.
Target sample size: 1600 people (Condition A: 340; Condition B: 630; Condition C: 630) provides at least 80 % power at p = 0.05 to detect a 5 % difference in abstinence rates between each condition.

Discussion

This trial will provide data on tobacco harm-reduction approaches and in particular the use of e-cigarettes as a replacement for smoking.

Trial registration

Australian and New Zealand Clinical Trials Registry: ACTRN12612001210​864. Date of registration: 15/11/2012.
Literature
1.
Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Med J Aust. 2008;188(1):36.PubMed
2.
Gartner CE, Barendregt JJ, Hall WD. Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when? Tob Control. 2009;18(3):183–9.CrossRefPubMed
3.
Gilmore AB, Britton J, Arnott D, Ashcroft R, Jarvis MJ. The place for harm reduction and product regulation in UK tobacco control policy. J Public Health. 2009;31(1):3–10.CrossRef
4.
Tobacco Working Group. Technical report no. 2. Tobacco control in Australia: making smoking history. Canberra: National Preventative Health Taskforce; 2008.
5.
Royal College of Physicians. Harm reduction in nicotine addiction: helping people who can’t quit. London: Tobacco Advisory Group of the Royal College of Physicians; 2007.
6.
Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet. 2007;369(9578):2010–4.CrossRefPubMed
7.
8.
Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20(5):218–25. doi:10.​1159/​000360220.CrossRefPubMed
9.
Gartner CE, Hall WD. Should Australia lift its ban on low nitrosamine smokeless tobacco products? Med J Aust. 2008;188(1):44.PubMed
10.
11.
Kozlowski LT, O’Connor R, Edwards BQ. Some practical points on harm reduction: what to tell your lawmaker and what to tell your brother about Swedish snus. Tob Control. 2003;12(4):372–3.PubMedCentralCrossRefPubMed
12.
Commonwealth of Australia. National Tobacco Strategy 2012–2018: a strategy to improve the health of all Australians by reducing the prevalence of smoking and its associated health, social and economic costs, and the inequalities it causes. Canberra: Commonwealth of Australia; 2012.
13.
National Institute for Health and Care Excellence. Tobacco: harm-reduction approaches to smoking. London: National Institute for Health and Care Excellence; 2013.
14.
Australian Government Department of Health, Therapeutic Goods Administration. The poisons standard (the SUSMP). Canberra: Commonwealth of Australia; 2015.
15.
Stead L, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane DB Syst Rev. 2012;11:CD000146.
16.
Douglas H, Hall W, Gartner C. E-cigarettes and the law in Australia. Aust Fam Physician. 2015;44(6):415–8.PubMed
17.
18.
19.
Action on Smoking and Health. Use of electronic cigarettes (vapourisers) among adults in Great Britain. London: ASH; 2014.
20.
Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382:1629–37.CrossRefPubMed
21.
22.
Hyland A, Laux FL, Higbee C, Hastings G, Ross H, Chaloupka F, et al. Cigarette purchase patterns in four countries and the relationship with cessation: findings from the International Tobacco Control (ITC) Four Country Survey. Tob Control. 2006;15 Suppl 3:iii59–64.PubMedCentralPubMed
23.
Heatherton TF, Kozlowski LT, Frecker RC, Rickert W, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84(7):791–9.CrossRefPubMed
24.
25.
Australian Institute of Health and Welfare. 2013 National Drug Strategy Household Survey: detailed findings. Canberra: AIHW; 2014.
26.
Yingst JM, Veldheer S, Hrabovsky S, Nichols TT, Wilson SJ, Foulds J. Factors associated with electronic cigarette users’ device preferences and transition from first generation to advanced generation devices. Nicotine Tob Res. 2015. doi:10.​1093/​ntr/​ntv052.
Metadata
Title
Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokers
Authors
Doug Fraser
Ron Borland
Coral Gartner
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2015
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-015-2366-1

Other articles of this Issue 1/2015

BMC Public Health 1/2015 Go to the issue

Research article

Does parental monitoring moderate the relationship between bullying and adolescent nonsuicidal self-injury and suicidal behavior? A community-based self-report study of adolescents in Germany

Research article

Country-level and individual correlates of overweight and obesity among primary school children: a cross-sectional study in seven European countries

Research article

Optimizing strategies for population-based chlamydia infection screening among young women: an age-structured system dynamics approach

Study protocol

Evaluation of a Web-based tailored intervention (TAVIE en santé) to support people living with HIV in the adoption of health promoting behaviours: an online randomized controlled trial protocol

Research article

Installation of a stationary high desk in the workplace: effect of a 6-week intervention on physical activity

Research article

Attitudes and avatars instrument: development and initial testing